Skip to main content
. 2021 Nov 22;82(2):264–277. doi: 10.1158/0008-5472.CAN-21-1171

Figure 6.

Figure 6. NK cells contribute to BAFF-triggered differences in tumor growth. A–F, C57BL/6 (B6) or Ifng−/− mice were inoculated subcutaneously with 5 × 105 of BAFF-expressing or control cells and tumors were analyzed 13 days post-inoculation. A, Left, numbers of CD8+ T-cell infiltrates in BAFF and control tumors were analyzed using FACS (n = 6, pooled from two independent in vivo experiments; right) as were number of IFNγ+ CD8+ T cells (n = 4; right). B, Tumor growth was followed in Cd8−/− mice (n = 3–6). C, Numbers of Nk1.1+ cell infiltrates in tumors were analyzed using FACS (n = 9–10, pooled from three independent in vivo experiments). D, Tumor growth was followed in C57BL/6 mice treated with NK-cell depleting antibody (anti-Nk1.1; n = 5). E, Granzyme B (GZMB) and IFNγ intracellular expression was measured in tumor-infiltrating Nk1.1 cells using FACS analysis at day 13 after tumor inoculation (n = 3–5). F, Tumor growth was followed in Ifng−/− and C57BL/6 (B6) mice (n = 5–8, pooled from two independent in vivo experiments). G and H, The ability of BAFF (1 μg)-treated NK cells (G) or NK cells combined with monocytes harvested from BAFF-expressing or control tumors (H) to kill RMA/S cell was measured at the indicated effector/target ratios (n = 3). Error bars in all experiments indicate SEM. *, P < 0.05 as determined by a Student t test (unpaired, two-tailed) or a two-way ANOVA with a post hoc test.

NK cells contribute to BAFF-triggered differences in tumor growth. A–F, C57BL/6 (B6) or Ifng−/− mice were inoculated subcutaneously with 5 × 105 of BAFF-expressing or control cells and tumors were analyzed 13 days post-inoculation. A, Left, numbers of CD8+ T-cell infiltrates in BAFF and control tumors were analyzed using FACS (n = 6, pooled from two independent in vivo experiments; right) as were number of IFNγ+ CD8+ T cells (n = 4; right). B, Tumor growth was followed in Cd8−/− mice (n = 3–6). C, Numbers of Nk1.1+ cell infiltrates in tumors were analyzed using FACS (n = 9–10, pooled from three independent in vivo experiments). D, Tumor growth was followed in C57BL/6 mice treated with NK-cell depleting antibody (anti-Nk1.1; n = 5). E, Granzyme B (GZMB) and IFNγ intracellular expression was measured in tumor-infiltrating Nk1.1 cells using FACS analysis at day 13 after tumor inoculation (n = 3–5). F, Tumor growth was followed in Ifng−/− and C57BL/6 (B6) mice (n = 5–8, pooled from two independent in vivo experiments). G and H, The ability of BAFF (1 μg)-treated NK cells (G) or NK cells combined with monocytes harvested from BAFF-expressing or control tumors (H) to kill RMA/S cell was measured at the indicated effector/target ratios (n = 3). Error bars in all experiments indicate SEM. *, P < 0.05 as determined by a Student t test (unpaired, two-tailed) or a two-way ANOVA with a post hoc test.